复宏汉霖(02696.HK)：HLX11获欧盟CHMP积极审评意见 有望获批欧盟上市

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), announced that its drug HLX11 has received a positive review opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending approval for its marketing authorization application [1] Group 1 - The CHMP's review opinion will be submitted to the European Commission (EC), which will consider this opinion and make a final review decision in the next 2-3 months [1] - If approved by the EC, the centralized marketing authorization for HLX11 will take effect in all EU member states and the European Economic Area (EEA) countries, including Iceland, Liechtenstein, and Norway [1]